Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...